Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients

European Journal of Clinical Pharmacology

Volumn 68, Issue 10, 2012, Pages 1395-1401

  Chu, Xiao Man ^a   Zhang, Li Fang ^b   Wang, Guang Ji ^b   Zhang, Shen Ning ^a   Zhou, Jia Hui ^a   Hao, Hai Ping ^b  

^a JINLING HOSPITAL   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Drug combination; Pharmacokinetics; Polymorphisms; UDP glucuronosyltransferase; Valproic acid

Indexed keywords

CARBAMAZEPINE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B7; VALPROIC ACID;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG METABOLISM; EPILEPSY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UGT1A3 GENE; UGT1A6 GENE; UGT2B7 GENE;

ADULT; ALLELES; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; EPILEPSY; FEMALE; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; VALPROIC ACID;

EID: 84866619971     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1277-7     Document Type: Article

References (38)

1. Rogawski MA, Loscher W (2004) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10:685-692
2. Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110:943-954
3. Patsalos PN, Perucca E (2003) Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2:473-481
4. Nakajima Y, Mizobuchi M, Nakamura M et al (2004) Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 32:1383-1391
5. Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246-255
6. Chung JY, Cho JY, Yu KS et al (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83:595-600
7. Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554-563
8. Zaccara G, Messori A, Moroni F (1988) Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 15:367-389
9. Reith DM, Andrews J, Parker-Scott S et al (2000) Urinary excretion of valproate metabolites in children and adolescents. Biopharm Drug Dispos 21:327-330
10. Dickinson RG, Hooper WD, Dunstan PR et al (1989) Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit 11:127-133
11. Argikar UA, Remmel RP (2009) Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP- glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 37:229-236
12. Burchell B, Brierley CH, Monaghan G et al (1998) The structure and function of the UDP-glucuronosyltransferase gene family. Adv Pharmacol 42:335-338
13. Mackenzie PI, Owens IS, Burchell B et al (1997) The UDPglycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269
14. Ethell BT, Anderson GD, Burchell B (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP- glucuronosyltransferases. Biochem Pharmacol 65:1441-1449
15. Green MD, King CD, Mojarrabi B et al (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDPglucuronosyltransferase 1A3. Drug Metab Dispos 26:507-512
16. Krishnaswamy S, Hao Q, Al-Rohaimi A et al (2005) UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 313:1340-1346
17. Caillier B, Lepine J, Tojcic J et al (2007) A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenet Genomics 17:481-495
18. Chen Y, Chen S, Li X et al (2006) Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population. Drug Metab Dispos 34:1462-1467
19. Riedmaier S, Klein K, Hofmann U et al (2010) UDPglucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 87:65-73
20. Kodama Y, Koike Y, Kimoto H et al (1992) Binding parameters of valproic acid to serum protein in healthy adults at steady state. Ther Drug Monit 14:55-60
21. Kagaya H, Inoue K, Miura M et al (2007) Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:279-288
22. Iwuchukwu OF, Ajetunmobi J, Ung D et al (2009) Characterizing the effects of common UDP glucuronosyltransferase (UGT) 1A6and UGT1A1 polymorphisms on cis- and trans-resveratrol glucuronidation. Drug Metab Dispos 37:1726-1732
23. Tan L, Yu JT, Sun YP et al (2010) The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 112:320-323
24. Iwai M, Maruo Y, Ito M et al (2004) Six novel UDPglucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 49:123-128
25. Ehmer U, Vogel A, Schutte JK et al (2004) Variation of hepatic glucuronidation: novel functional polymorphisms of the UDPglucuronosyltransferase UGT1A4. Hepatology 39:970-977
26. Xing Y, Yang L, Wang L et al (2009) Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. Pharmacogenomics 10:741-752
27. Saeki M, Saito Y, Jinno H et al (2005) Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet 20:85-90
28. Lampe JW, Bigler J, Horner NK et al (1999) UDPglucuronosyltransferase (UGT1A1) 28 and UGT1A62) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9:341-349
29. Menard V, Girard H, Harvey M et al (2009) Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat 30:677-687
30. Lin GF, Guo WC, Chen JG et al (2005) An association of UDPglucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 85:502-506
31. Saeki M, Saito Y, Jinno H et al (2006) Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 6:63-75
32. Kohle C, Mohrle B, Munzel PA et al (2003) Frequent cooccurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A128) with other polymorphisms of the UDPglucuronosyltransferase- 1 locus (UGT1A62 and UGT1A73) in Caucasians and Egyptians. Biochem Pharmacol 65:1521-1527
33. Maruo Y, Iwai M, Mori A et al (2005) Polymorphism of UDPglucuronosyltransferase and drug metabolism. Curr Drug Metab 6:91-99
34. Burchell B (2003) Genetic variation of human UDPglucuronosyltransferase: implications in disease and drug glucuronidation. Am J Pharmacogenomics 3:37-52
35. Kwara A, Lartey M, Boamah I et al (2009) Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B71c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 49:1079-1090
36. Gutierrez K, Walter H, Bankier B (1999) Valproic acid and Carbamazepine: a successful antipsychotic medication? The problem of diagnosis and its relevance for therapy. Psychopathology 32:235-241
37. Chung JY, Cho JY, Yu KS et al (2005) Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther 77:486-494
38. Kiang TK, Ensom MH, Chang TK (2005) UDPglucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132